Resistin: Potential biomarker and therapeutic target in atherosclerosis

Li Zhou,Jun-Yi Li,Ping-Ping He,Xiao-Hua Yu,Chao-Ke Tang
DOI: https://doi.org/10.1016/j.cca.2020.11.010
IF: 6.314
2021-01-01
Clinica Chimica Acta
Abstract:<p>Resistin, a cysteine-rich secretory protein, has a pleiotropic role in humans. Resistin usually presents as trimer or hexamer in plasma, and targets specific receptors Toll Like Receptor 4 (TLR4) or Adenylyl Cyclase-Associated Protein 1 (CAP1). Upon binding to TLR4 and CAP1, resistin can trigger various intracellular signal transduction pathways to induce vascular inflammation, lipid accumulation, and plaque vulnerability. These pro-atherosclerotic effects of resistin appear in various cell types, including endothelial cells, vessel smooth muscle cells and macrophages, which cause diverse damages to cardiovascular system from dyslipidemia, atherosclerosis rupture and ventricular remodeling. In this review, we gather recent evidence about the pro- atherosclerotic effects of resistin and highlight it as a candidate therapeutic or diagnostic target for cardiovascular disease.</p>
medical laboratory technology
What problem does this paper attempt to address?